Below are the most recent publications written about "Warfarin" by people in Profiles.
-
Rhoney DH, La M, Merz M, Cook A, Owusu KA, Roels C, Blunck J, Shewmaker J, Sangha KS, Farrokh S, Lewin J, Chester KW, Human T, Bledsoe K, Greene K, Levesque M, Rocker JC, Davis G, Neyens R, Lassiter TF, Adriance SM. Inactivated Four-Factor Prothrombin Complex Concentrate Dosing Practices for Reversal of Warfarin-Related Intracranial Hemorrhage. Neurocrit Care. 2021 08; 35(1):130-138.
-
Lam PH, Packer M, Gill GS, Wu WC, Levy WC, Zile MR, Brar V, Arundel C, Cheng Y, Singh SN, Allman RM, Fonarow GC, Ahmed A. Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. Am J Med. 2020 10; 133(10):1187-1194.
-
Sasso R, Rockey DC. Controversies in anticoagulation therapy in patients with cirrhosis. Curr Opin Gastroenterol. 2019 05; 35(3):161-167.
-
Coleman CI, Weeda ER, Nguyen E, Bunz TJ, Sood NA. Effectiveness and safety of rivaroxaban vs. warfarin in patients 80+ years of age with non-valvular atrial fibrillation. Eur Heart J Qual Care Clin Outcomes. 2018 10 01; 4(4):328-329.
-
Roberts MZ, Gaskill GE, Kanter-Washko J, Kyle TR, Jones BC, Bohm NM. Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study. J Thromb Thrombolysis. 2018 May; 45(4):512-515.
-
Coleman CI, Vaitsiakhovich T, Nguyen E, Weeda ER, Sood NA, Bunz TJ, Schaefer B, Meinecke AK, Eriksson D. Agreement between coding schemas used to identify bleeding-related hospitalizations in claims analyses of nonvalvular atrial fibrillation patients. Clin Cardiol. 2018 Jan; 41(1):119-125.
-
Brodie MM, Newman JC, Smith T, Rockey DC. Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral Anticoagulants. Am J Med. 2018 05; 131(5):573.e9-573.e15.
-
Pan KL, Singer DE, Ovbiagele B, Wu YL, Ahmed MA, Lee M. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2017 Jul 18; 6(7).
-
Weeda ER, Peacock WF, Fermann GJ, Baugh CW, Wells PS, Ashton V, Crivera C, Wildgoose P, Schein JR, Coleman CI. Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. Int J Clin Pract. 2017 Jan; 71(1).
-
Weeda ER, Wells PS, Peacock WF, Fermann GJ, Baugh CW, Ashton V, Crivera C, Wildgoose P, Schein JR, Coleman CI. Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin. Intern Emerg Med. 2017 Apr; 12(3):311-318.